

# Glibenclamide Improves Neurological and Electrophysiological Recovery after

## Cardiac Arrest

Brittany Bolduc Lachance, DO<sup>1-2</sup>, Zhuoran Wang, MD, MS<sup>3</sup>, Neeraj Badjatia, MD, MS<sup>1-2</sup>, Xiaofeng Jia, MD, PhD<sup>3-7</sup>



<sup>1</sup>Program in Trauma, Departments of <sup>2</sup>Neurology, <sup>3</sup>Neurosurgery, <sup>4</sup>Orthopedics, <sup>5</sup>Anatomy and Neurobiology University of Maryland School of Medicine Departments of <sup>6</sup>Biomedical Engineering, <sup>7</sup>Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD


#### Introduction

- Glibenclamide (GBC) is a secondgeneration sulfonylurea working via inhibition of SUR-1 receptors
- GBC has been shown to improve neurological outcome in animal cardiac arrest (CA) models
- Somatosensory evoked potentials (SSEPs) are considered a reliable tool for prognostication after CA
- We analyzed the effects of GBC on SSEP recovery post-CA


#### Methods

- 16 male Wistar rats subjected to 8-min asphyxia CA randomized to control group (n=8) or GBC group (n=8)
- GBC loading dose 10ug/kg 10min after ROSC; maintenance dose 1.6ug/kg q8h for 24 hours; control received equivalent volume of saline
- SSEP recorded baseline and q15min for 150 minutes following CA
- Subset of neurological deficit score A & B evaluating arousal and brainstem reflexes analyzed at 6, 24, 48, and 72 hours
- Univariate analysis comparing SSEP N10 amplitude between the two groups
- ANOVA test compared SSEP recovery at 30, 60, 90, and 120min post-CA


### Results – Somatosensory Evoked Potential Recovery



## SSEP N10 Amplitude Baseline vs. 120min



#### Results – Functional Recovery



#### Discussion

- **GBC improves SSEP recovery post-CA**, with N10 amplitude reaching baseline at 120 minutes compared to control
- GBC improves coma recovery and survival after CA
- GBC warrants further exploration as a potential drug therapy to improve functional and electrophysiologic outcomes after CA

Acknowledgement: Supported by NIH R01HL118084 and RO1NS110387 (both to XJ)